Abstract
(11.1%) for the high AUC subgroup. Allergic manifestations were felt to be treatment related in 2% and led to study withdrawal for 1.5% of ISIS 2302 subjects. The maximum postinfusion aPTF averaged 42 seconds (individual peak 47.4) in the high AUC subgroup, a class effect of phosphorothiorate oligonucleotides, without reported bleeding. This study supports a future evaluation of ISIS 2302 to block ICAM-1 expression at higher dose levels in Crohn s disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
